Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

A Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal Women

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.

Who May Be Eligible (Plain English)

Who May Qualify: - Female, post-menopausal, age ≥ 55 years old - Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months. - Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\<103 colony forming units per ml of urine). - Able to attend all follow-up appointments for the study. - A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum. Who Should NOT Join This Trial: - Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period. - Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion. - Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period. - Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank/lumbar pain or tenderness - Diagnosis of interstitial cystitis or overactive bladder syndrome - Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months - Use of Uromune or other vaccine approaches to reduce rUTI - Participation in a research study involving an investigational product in the past 12 weeks - Receipt of phage treatment - History of chronic diarrhea requiring regular therapy - Inability to swallow or known history of gastrointestinal malabsorption - History of recurrent vaginal yeast infections ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Female, post-menopausal, age ≥ 55 years old * Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months. * Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\<103 colony forming units per ml of urine). * Able to attend all follow-up appointments for the study. * A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum. Exclusion Criteria: * Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period. * Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion. * Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period. * Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank/lumbar pain or tenderness * Diagnosis of interstitial cystitis or overactive bladder syndrome * Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months * Use of Uromune or other vaccine approaches to reduce rUTI * Participation in a research study involving an investigational product in the past 12 weeks * Receipt of phage treatment * History of chronic diarrhea requiring regular therapy * Inability to swallow or known history of gastrointestinal malabsorption * History of recurrent vaginal yeast infections * Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \[creatinine \> 1.5 g/dl\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet). * Nursing home resident * BMI \>40 Box 1 Supplements to avoid * Multi-Vitamins and Multi-Mineral capsules * Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen) * Probiotics * Cranberry Mannose or Cranberry Extract Weight loss products to avoid * Medifast * Vitafusion * OptiVin Products * Appetite Suppressants * Keto-Fuel

Treatments Being Tested

DIETARY_SUPPLEMENT

D-Mannose

D-mannose (2g, i.e., 4 x 500mg capsules) daily for 12 months.

DIETARY_SUPPLEMENT

Placebo

Placebo daily for 12 months.

Locations (1)

University of Texas Southwestern Medical Center
Dallas, Texas, United States